Combination antifungal therapy for invasive aspergillosis [10] (multiple letters)

Clinical Infectious Diseases

Volumn 40, Issue 7, 2005, Pages 1073-1076

  Cesaro, Simone ^a   Visintin, Gianluca ^a   Marr, Kieren A ^b   Boeckh, Michael ^b   Hyung, Woo Kim ^b  

^a UNIVERSITY OF PADOVA   (Italy)

^b Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; CASPOFUNGIN; ECHINOCANDIN; POLYENE; PYRROLE; VORICONAZOLE;

ASPERGILLOSIS; COST BENEFIT ANALYSIS; DOSE RESPONSE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HIGH RISK PATIENT; HUMAN; IMMUNE DEFICIENCY; LETTER; MAINTENANCE THERAPY; MORTALITY; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; RELAPSE; SALVAGE THERAPY; STANDARDIZATION; SURVIVAL RATE; TREATMENT OUTCOME;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; ASPERGILLOSIS; DRUG THERAPY, COMBINATION; HUMANS; PEPTIDES, CYCLIC; PYRIMIDINES; TRIAZOLES;

EID: 15744365906     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/428674     Document Type: Letter

References (0)